Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: Preliminary results of a case-control study

European Journal of Surgical Oncology

Volumn 36, Issue 6, 2010, Pages 575-582

  Pessaux, P ^a   Panaro, F ^a   Casnedi, S ^a   Zeca, I ^a   Marzano, E ^a   Bachellier, P ^a   Jaeck, D ^a   Chenard, M P ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Bevacizumab; Cetuximab; Colorectal metastases; Hepatectomy; Hepatotoxicity; Morbidity; Targeted molecular therapy

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CEFAZOLIN; CETUXIMAB; LOW MOLECULAR WEIGHT HEPARIN;

ADJUVANT CHEMOTHERAPY; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE CONTROL STUDY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; LIVER FAILURE; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LUNG EMBOLISM; LUNG PARENCHYMA; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATIENT SELECTION; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTHROMBIN TIME; URINARY TRACT INFECTION; WOUND INFECTION;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; POSTOPERATIVE COMPLICATIONS; SEX FACTORS; STATISTICS, NONPARAMETRIC;

EID: 77953121574     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.04.010     Document Type: Article

References (30)

1. Simmonds P.C., Primrose J.N., Colquitt J.L., et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94 (2006) 982-999
2. Jaeck D., and Pessaux P. Bilobar colorectal liver metastases: treatment options. Surg Oncol Clin N Am 17 (2008) 553-568
3. Nordlinger B., Sorbye H., Collette L., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008) 1007-1016
4. Rubbia-Brandt L., Audard V., Sartorelli P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004) 460-466
5. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after pre-operative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24 (2006) 845-853
6. Karoui M., Penna C., Amin-Hashem M., et al. Influence of chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243 (2006) 1-7
7. Nakano H., Oussoultzoglou E., Rosso E., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247 (2008) 118-124
8. Fernandez F.G., Ritter J., Goodwin J.W., et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pre-treatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200 (2005) 845-853
9. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (2006) 2065-2072
10. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
11. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
12. Adam R., Aloia T., Levi F., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25 (2007) 4593-4602
13. D'Angelica M., Kornprat P., Gonen M., et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14 (2006) 759-765
14. Reddy S.K., Morse M.A., Hurwitz H.I., et al. Addition of bevacizumab to irinotecan and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206 (2008) 96-106
15. Ribero D., Wang H., Donadon M., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110 (2007) 2761-2767
16. Klinger M., Eipeldauer S., Hacker S., et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35 (2009) 515-520
17. Dindo D., Demartines N., and Clavien P.A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240 (2004) 205-213
18. Balzan S., Belghiti J., Farges O., et al. The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 242 (2005) 824-829
19. Ozier Y., Pessione F., Samain E., et al. French study group on blood transfusion in liver transplantation. Institutional variability in transfusion practice for liver transplantation. Anesth Analg 97 (2003) 671-679
20. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
21. Brunt E.M. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 31 (2000) 241-246
22. Nordlinger B., Guiguet M., Vaillant J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection based on 1568 patients. Cancer 77 (1996) 1254-1262
23. Fong Y., Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999) 309-321
24. Parc Y., Dugue L., Farges O., et al. Preoperative systemic 5-fluorouracil does not increase the risk of liver resection. Hepatogastroenterology 47 (2000) 1703-1705
25. Parikh A.A., Gentner B., Wu T.T., et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 7 (2003) 1082-1088
26. Scoggins C.R., Campbell M.L., Landry C.S., et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 16 (2009) 35-41
27. Suc B., Panis Y., Belghiti J., et al. Natural history of hepatectomy. Br J Surg 79 (1992) 39-42
28. Rubbia-Brandt L., Mentha G., and Terris B. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll Surg 202 1 (2006 Jan) 199-200
29. Zorzi D., Laurent A., Pawlik T.M., et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94 (2007) 274-286
30. Welsh F.K., Tilney H.S., Tekkis P.P., et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 96 7 (2007 Apr 10) 1037-1042